Natera agreed to acquire Foresight Diagnostics for about $275 million to gain phased‑variant enrichment and detection sequencing technology aimed at improving minimal residual disease (MRD) sensitivity. Natera said the deal will accelerate its move into hematologic oncology and bolster its Signatera solid‑tumor MRD assay. Separately, Natera partnered with MEDSIR on the MiRaDoR Phase II trial, which will use Signatera Genome to guide investigational treatment arms in early HR+/HER2‑ breast cancer. The trial is designed to test ctDNA‑directed therapeutic sequencing and to evaluate combo regimens including oral SERDs and targeted agents. Natera framed the moves as a dual strategy: enhance assay sensitivity with phased‑variant methods while embedding Signatera into MRD‑driven clinical trials to support broader clinical adoption and reimbursement.